Antibody-Drug Conjugates in Oncology: Mechanisms, Clinical Progress, and Future Directions
Cancer Biome and Targeted Therapy · 12.05.2026 · 35-83
DOI: 10.66505/cbtt.v1i2.32 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Biome and Targeted Therapy, online erschienen am 12.05.2026. Verfasst von Zichun Zhu und 7 weiteren Autor:innen. Die Arbeit nennt 222 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Beijing Xisike Clinical Oncology Research Foundation, China Postdoctoral Science Foundation, Natural Science Foundation of Zhejiang Province.
Abstract (Originalsprache)
Antibody-drug conjugates (ADCs) are a rapidly evolving therapeutic modality that integrates the target specificity of monoclonal antibodies with the potent cytotoxicity of small-molecule drugs, thereby redefining precision oncology. By enabling selective delivery of highly toxic payloads to malignant cells, ADCs aim to maximize antitumor efficacy while limiting systemic toxicity. This review provides a comprehensive overview of ADC development, focusing on the rational design and functional interplay of the four core components: tumor-associated antigens, antibody scaffolds, linker chemistries, and cytotoxic payloads. Key considerations in target selection, antibody isotype choice, linker stability and cleavage mechanisms, and payload potency are discussed in detail. In addition, we summarize the principal in vivo mechanisms underlying ADC activity, including canonical intracellular payload release, bystander killing, antibody-mediated immune effector functions, and immunogenic cell death. These mechanisms collectively contribute to therapeutic efficacy, particularly in heterogeneous and treatment-resistant tumors. The review also provides an updated overview of 19 antibody-drug conjugates that have received regulatory approval worldwide, highlighting their clinical indications, linker-payload combinations, and representative efficacy outcomes. Safety profiles and treatment-related toxicities are examined, with emphasis on class-specific adverse events and tolerability considerations observed in clinical practice. Finally, we discuss emerging strategies and unresolved challenges in ADC development, including resistance mechanisms, linker-payload optimization, novel target discovery, and integration with immunotherapy and combination regimens. By synthesizing current clinical progress with mechanistic and technological insights, this review serves as a comprehensive reference to support future preclinical research, clinical trial design, and the rational advancement of next-generation ADC-based cancer therapies.
Förderung
- Beijing Xisike Clinical Oncology Research Foundation
- China Postdoctoral Science Foundation
- Natural Science Foundation of Zhejiang Province
- Key Laboratory of Yarn Materials Forming and Composite Processing Technology of Zhejiang Province, Jiaxing University,National Postdoctoral Program for Innovat…
- National Natural Science Foundation of China
Zitieren
APA
Zhu, Z., Wang, S., Hong, W., Zhong, Q., Wang, W., Wang, N., Bai, M., & Zhu, J. (2026). Antibody-Drug Conjugates in Oncology: Mechanisms, Clinical Progress, and Future Directions. Cancer Biome and Targeted Therapy, 35-83. https://doi.org/10.66505/cbtt.v1i2.32
Vancouver
Zhu Z, Wang S, Hong W, Zhong Q, Wang W, Wang N, et al. Antibody-Drug Conjugates in Oncology: Mechanisms, Clinical Progress, and Future Directions. Cancer Biome and Targeted Therapy. 2026:35-83. doi:10.66505/cbtt.v1i2.32
BibTeX
@article{Zhu2026,
author = {Zhu, Zichun and Wang, Siwei and Hong, Weifeng and Zhong, Qingping and Wang, Weixin and Wang, Nan and Bai, Minghua and Zhu, Ji},
title = {Antibody-Drug Conjugates in Oncology: Mechanisms, Clinical Progress, and Future Directions},
journal = {Cancer Biome and Targeted Therapy},
year = {2026},
pages = {35--83},
doi = {10.66505/cbtt.v1i2.32}
}
EUVIMED